X
Xiaolei Li
Researcher at University of California, San Francisco
Publications - 17
Citations - 2224
Xiaolei Li is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Protein kinase B & PI3K/AKT/mTOR pathway. The author has an hindex of 14, co-authored 17 publications receiving 1671 citations. Previous affiliations of Xiaolei Li include Fourth Military Medical University & Peking University.
Papers
More filters
Journal ArticleDOI
Circular RNA: A new star of noncoding RNAs
Shibin Qu,Xisheng Yang,Xiaolei Li,Jianlin Wang,Yuan Gao,Runze Shang,Wei Sun,Kefeng Dou,Haimin Li +8 more
TL;DR: Similar to miRNAs and long noncoding RNAs (lncRNAs), circRNAs are becoming a new research hotspot in the field of RNA and could be widely involved in the processes of life.
Journal ArticleDOI
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis
Pin Liu,Mengmeng Ge,Junjie Hu,Xiaolei Li,Li Che,Kun Sun,Lili Cheng,Yuedong Huang,Maria G. Pilo,Antonio Cigliano,Giovanni Mario Pes,Rosa Maria Pascale,Stefania Brozzetti,Gianpaolo Vidili,Alberto Porcu,Antonio Cossu,Giuseppe Palmieri,Maria Cristina Sini,Silvia Ribback,Frank Dombrowski,Junyan Tao,Diego F. Calvisi,Ligong Chen,Xin Chen +23 more
TL;DR: It is demonstrated that the mammalian target of rapamycin complex 1 (mTORC1) cascade is activated and necessary for c‐Myc‐dependent hepatocarcinogenesis and targeting the mTOR pathway or amino acid transporters may be an effective and novel therapeutic option for the treatment of hepatocellular carcinoma with activated c‐ myc signaling.
Journal ArticleDOI
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
Lei Li,Giulia M. Pilo,Xiaolei Li,Antonio Cigliano,Gavinella Latte,Li Che,Christy Joseph,Marta Mela,Chunmei Wang,Lijie Jiang,Silvia Ribback,Maria Maddalena Simile,Rosa Maria Pascale,Frank Dombrowski,Matthias Evert,Clay F. Semenkovich,Xin Chen,Diego F. Calvisi +17 more
TL;DR: FASN is not oncogenic per se in the mouse liver, but is necessary for AKT-driven hepatocarcinogenesis and pharmacological blockade of FASN might be highly useful in the treatment of human HCC characterized by activation of the AKT pathway.
Journal ArticleDOI
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Junjie Hu,Li Che,Lei Li,Lei Li,Maria G. Pilo,Antonio Cigliano,Silvia Ribback,Xiaolei Li,Xiaolei Li,Gavinella Latte,Marta Mela,Matthias Evert,Frank Dombrowski,Guohua Zheng,Xin Chen,Xin Chen,Diego F. Calvisi +16 more
TL;DR: It is demonstrated that co-activation of AKT and c-Met induces HCC development that depends on the mTORC1/FASN pathway, and suppression of m TORC1 and/or FASN might be highly detrimental for the growth of human HCC subsets characterized by concomitant induction of the AKT/c-Met cascades.
Journal ArticleDOI
Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Junyan Tao,Emily Xu,Yifei Zhao,Sucha Singh,Xiaolei Li,Gabrielle Couchy,Xin Chen,Jessica Zucman-Rossi,Maria Chikina,Satdarshan P.S. Monga +9 more
TL;DR: A cooperation of hMet and β‐catenin activation in a subset of HCC patients is identified and modeled this human disease in mice with a significant transcriptomic intersection to provide novel insight into the biology of this tumor and allow us to evaluate novel therapies as a step toward precision medicine.